Abstract-Vascular smooth muscle cells (VSMCs) play a role in the development of vascular disease, for example, neointimal formation, arterial aneurysm, and Marfan syndrome caused by genetic mutations in VSMCs, but little is known about the mechanisms of the disease process. Advances in induced pluripotent stem cell technology have now made it possible to derive VSMCs from several different somatic cells using a selection of protocols. As such, researchers have set out to delineate key signaling processes involved in triggering VSMC gene expression to grasp the extent of gene regulatory networks involved in phenotype commitment. This technology has also paved the way for investigations into diseases affecting VSMC behavior and function, which may be treatable once an identifiable culprit molecule or gene has been repaired. Moreover, induced pluripotent stem cell-derived VSMCs are also being considered for their use in tissue-engineered blood vessels as they may prove more beneficial than using autologous vessels. Finally, while several issues remains to be clarified before induced pluripotent stem cell-derived VSMCs can become used in regenerative medicine, they do offer both clinicians and researchers hope for both treating and understanding vascular disease. In this review, we aim to update the recent progress on VSMC generation from stem cells and the underlying molecular mechanisms of VSMC differentiation. We will also explore how the use of induced pluripotent stem cell-derived VSMCs has changed the game for regenerative medicine by offering new therapeutic avenues to clinicians, as well as providing researchers with a new platform for modeling of vascular disease. Visual Overview-An online visual overview is available for this article.
S mooth muscle cells (SMCs) form part of a large network of nonstriated muscle that extends from the inner lining of hollow organs, such as the intestinal and respiratory tracts, to the central layers of all major blood vessels. 1, 2 To this end, SMCs can fulfill their role by ensuring synchronized, unidirectional movement of the organ's contents. Vascular smooth muscle cells (VSMCs) are the SMC population resident in all major blood vessels. 3 Their ability to contract and relax in response to nerve signals and locally released vasoactive mediators forms part of the overall regulation of vascular tone and blood pressure. 4, 5 Under homeostatic conditions, VSMCs are predominantly located in the medial layer of blood vessels and live in a quiescent contractile state. However, their inherent plasticity allows them to undergo phenotypic dedifferentiation and adopt a synthetic proinflammatory phenotype in response to vascular injury or during disease. 6, 7 These highly proliferative VSMCs can then migrate into the neointima of diseased or injured blood vessels to form part of restenosis lesions. 8 Equally, phenotypic alterations in VSMCs can lead to increased matrix protein productions resulting in diseases such as Marfan syndrome, a connective tissue disorder responsible for life threatening pathologies such as the thoracic aortic aneurysms and aortic dissection. 9 A study conducted in mice found that mutations in the polycystic kidney disease 1 gene increases VSMC apoptosis thereby inducing dissecting aneurysms, highlighting the importance of maintaining VSMC homeostasis. 10 Thus, not only is VSMC integrity dependant on external factors such as endothelial disruption during atherosclerosis or genetic mutations within other cell types, but behavioral changes from the VSMC itself will in turn affect the direction of disease progression. Although VSMCs are a key component in the development of vascular diseases, the molecular mechanisms occurring as a result of VSMC alterations remain to be fully understood.
In cases of severe vascular injury, after a myocardial infarct or an in-stent restenosis, residual VSMC populations are not enough to constitute an effective restorative response in the midst of such a highly inflammatory and hypoxic environment. 11 Current therapies include vessel grafts that involve the use of replacement conduits such as internal mammary arteries or saphenous veins to provide an alternate route for blood flow. 12 The field of tissue engineering has advanced considerably over the past few years with the use of synthesized biocompatible vessel grafts emerging as an alternative to autologous vessels in transplantation therapy. 13 Since induced pluripotent stem cell (iPSC) technology was first introduced, it is now possible to generate an unlimited number of cells for use in tissue engineering techniques such as this.
14 Understanding how iPSC-derived VSMCs can be manipulated both in vitro and in vivo will surely benefit those looking to understand VSMC signaling processes and those wishing to harness their potential for regenerative therapies. As such, this review will cover our current understanding of VSMC differentiation from iPSCs based on previous study in pluripotent embryonic stem cells. In addition, we will examine the different protocols used to generate VSMCs from human iPSCs (hiPSCs). Finally, this review will explore how the use of iPSC-derived VSMCs has changed the game for regenerative medicine by offering new therapeutic avenues to clinicians, as well as providing researchers with a new platform for modeling vascular disease.
VSMC Origin and Differentiation
During embryonic development, VSMCs arise from several different lineages including the neural crest, secondary heart field, proepicardial organ, lateral plate mesoderm, and the paraxial mesoderm. 15 Accordingly, protocols used for the differentiation of pluripotent stem cells including embryonic stem cells and iPSCs are altered depending on the desired lineage of the VSMCs being generated. 16 For instance, a combination of BMP4 (bone morphogenic protein 4), activin and fibroblast growth factor 2 (FGF2) is required to generate mesodermal VSMCs. 17 Indeed Steinbach et al 18 2016 describe stepwise administration of key members of the transforming growth factor-β (TGF-β) superfamily to generate lateral plate-derived VSMCs from hPSCs. And more specifically proepicardial VSMCs are generated from hPSCs by precisely controlled administration of BMP2, 19 which crucially require activation of the BMP and Wnt signaling pathways to induce epithelial to mesenchymal transition for further specification toward the VSMC phenotype. 20 Meanwhile, neuroectoderm-derived VSMC generation requires FGF2 and activin inhibition, whereas paraxial mesoderm-derived VSMC generation requires initial BMP4 signaling with FGF2 and PI3K (phosphatidylinositol-4,5-bisphosphate 3-kinase) inhibition 21 ( Figure 1 ). Because iPSCs are derived from terminally differentiated cells, it is important to consider cell lineage commitment pathways during differentiation. 22 Establishing the existence of a VSMC population requires confirmation by analysis of appropriate gene and protein expression, as well as functional assessments by measuring contractile responses to a selection of agonists including carbachol, caffeine, and KCl. 22 As such, researchers seeking to delineate key signaling pathways required for the differentiation of stem cells into VSMCs use these as end points to determine whether a successful VSMC phenotype has been reached. This section does not cover all recognized signaling pathways regulating VSMC differentiation (eg, serum response factor [SRF]/myocardin complex, TGF-β, and platelet-derived growth factor-BB [PDGF-BB], Notch, retinoic acid, reactive oxygen species, small GTPase RhoA, and extracellular matrix-integrin signaling, as well as micro-RNAs), which has been extensively discussed in other reviews, [23] [24] [25] but instead summarizes the recent progress in this area ( Figure 2 ).
Recent studies have identified new key proteins required for the activation of VSMC-specific transcription factors involved in the upregulation of VSMC genes. [26] [27] [28] [29] [30] For instance, 2 hnRNPs (heterogeneous nuclear ribonucleoproteins), hnRNPA1 31 and hnRNPA2B1, 32 have been identified as key molecules for the regulation of VSMC differentiation from embryonic stem cells as it directly binds to promoter regions of VSMC-specific genes and transcription factors such as SRF and myocardin. hnRNPA1 also mediates its effect by recruiting Cbx3 (chromobox protein homolog gene 3), another VSMC differentiation regulatory nuclear protein. 33 Of note, knockdown of hnRNPA2B1 32 or Cbx3 33 was found to inhibit neural crest cell migration and differentiation into VSMCs, resulting in severe developmental defects of brachial arteries and reduced blood circulation in chick embryos. Similarly, a role for reactive oxygen species in regulating gene expression in stem cell-derived VSMCs has been characterized. 34, 35 Activation of the membrane-bound enzyme complex, nicotinamide adenine dinucleotide phosphate oxidase 4 has been shown to increase hydrogen peroxide release and enhance the expression of several VSMC transcription factors required for maintaining a VSMC phenotype. 34 Moreover, overexpression of the phospholipase A2 group 7 gene results in the activation of SMA-α (smooth muscle actin-α) and SM22α promoters by SRF in a superoxide-dependent manner leading to enhanced VSMC differentiation in stem cells, 36 a process that was shown to be under tight regulation by another transcription factor, nuclear factor erythroid 2-related factor 3. 37 Finally, several noncoding RNA molecules have also been implicated 39 Whereas micro-RNA-34a promotes expression of deacetylase sirtuin 1, a transcriptional activator of VSMC genes including those required for the SRF-myocardin binding complex. 40 TGF-β and PDGF-BB are 2 major growth factors that are responsible for inducing VSMC differentiation from stem/ progenitor cells. Indeed, inhibition of tyrosine kinase domains within the PDGFB receptor has been shown to inhibit VSMC marker expression in differentiating cardiovascular progenitor cells. 41 Equally TGF-β and PDGF-BB also play a role in dedifferentiation of VSMCs from their quiescent, contractile state toward a more proinflammatory synthetic phenotype. 42 As such, a significant amount of research has been dedicated to understanding the signaling pathways involved in bridging communication between the stimulated growth factor receptors and activation of the downstream VSMC genes. 28, [43] [44] [45] [46] [47] One study has identified a specific binding site for the transcription A B Figure 1 . Human pluripotent stem cells (huPSCs) differentiate into vascular smooth muscle cells (VSMCs) with different embryonic origins. HuPSCs can be differentiated down different embryonic routes in vitro using selection of growth factors and cytokines (A). huPSCsderived stem/progenitor cells can then be differentiated into specialized VSMCs phenotypes such as contractile or synthetic using a selection of growths factors (B). BMP indicates bone morphogenic protein; ECM, extracellular matrix protein; FBS, fetal bovine serum; FGF, fibroblast growth factor; PDGF-BB, platelet-derived growth factor-BB; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; TGF-β, transforming growth factor-β; and VEGF, vascular endothelial growth factor.
by guest on December 14, 2017 http://atvb.ahajournals.org/ Downloaded from factor, Sp1, which exists within the PDGF-BB responsive element of the histone deacetylase 7 promoter. 48 Previously, another study revealed that PDGF-mediated transcription of the histone deacetylase 7 results in alternative splicing of histone deacetylase 7 mRNA, which is crucial for the downstream modification of the SRF-myocardin complex, a pivotal step required for VSMC gene activation.
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VSMC Generation From hiPSCs
Although much of our understanding of VSMC differentiation originates from embryonic stem cell studies, iPSC technology offers a distinct advantage from both ethical and practical standpoint. 16 As such, iPSC research has garnered a lot of attention in recent years and several iPSC-VSMC differentiation protocols have been designed which are worth examining ( Figure 3 ).
Mesodermal-Derived Models Monolayer Method
Because a majority of VSMCs originate from the mesoderm during embryonic development, several protocols for generating VSMCs from iPSCs include a mesodermal step during differentiation before proceeding with differentiation toward a specialized VSMC phenotype. 50, 51 Using iPSCs generated from human cardiac fibroblasts, Yang et al 22 showed that mesodermal lineage commitment can be achieved in iPSCs by promoting BMP4 signaling and GSK3 (glycogen synthase kinase 3) inhibition. This was followed by VSMC-specific cytokine treatment, on matrigel-coated plates, resulting in a similar VSMC yield observed in hESCs undergoing the same regimen. 22 Both synthetic and contractile VSMCs could be generated from iPSCs by altering the VSMC growth factor cocktail administered to the differentiating cells. To a similar extent, Wanjare et al 52 treated hiPSCs, seeded onto collagen IV-coated plates, with medium containing high serum levels (10% fetal bovine serum), TGF-β1 (1 ng/mL), and PDGF-BB (10 ng/mL) to generate highly proliferative synthetic VSMCs, and serum starvation (0.5% fetal bovine serum) along with PDGF-BB deprivation to induce differentiation into the quiescent contractile VSMC phenotype ( Figure 1B ). Another study went a step further and differentiated iPSCs into vascular progenitor cells using key growth factors; BMP4 (50 ng/ mL), FGF2 (50 ng/mL) and human VEGF (vascular endothelial growth factor; 100 ng/mL). This was followed by simultaneous differentiation toward endothelial cell and VSMC commitment by seeding vascular progenitor cells onto fibronectin and collagen IV-coated dishes, respectively. Using this 2-step protocol, the authors of the study were able to expand hiPSC-derived mesodermal VSMCs have also been generated from mesenchymal stem cell intermediates using reprogrammed foreskin fibroblasts. 54 hiPSCs generated from reprogrammed hair follicle mesenchymal stem cells were used to generate multiple cells types including fat, bone, cartilage, and SMCs. Strikingly, these mesenchymal stem cell intermediates showed increased proliferative capacity and a higher clonogenic potential compared with the parent hair follicle mesenchymal stem cells, confirming hiPSC induction as a useful method for overcoming donor aging and culture senescence associated with using native multipotent stem cells. 55 
Embryoid Body Method
In addition to using the monolayer method, embryoid body (EB) formation is an alternative technique used to generate hiPSC-derived mesodermal lineage VSMCs. By allowing hiPSCs to aggregate in vitro, these pluripotent stem cells can undergo spontaneous differentiation into all 3 germ lines including the mesoderm. 56 After differentiation toward cardiovascular progenitor cell fate, enrichment of hiPSC-derived VSMCs can be achieved by negative selection to remove non-VSMCs. 57 Tissue-specific mesodermal VSMCs have also been generated via the EB method using a serum-free protocol to generate functional and clinically viable coronary arterylike VSMCs. 58 In fact, this study revealed that only at day 28 of EB formation did fully differentiated VSMCs appear and that these cells required the combined signaling of both VEGF and bFGF for maintenance of the phenotype ( Figure 1B) .
Establishing whether iPSC-derived VSMCs accurately reflect human VSMC behavior and function is essential to carry out investigations into VSMC cell signaling as well as harnessing these cells for regenerative therapies. As such, 1 group chose to generate iPSCs from hASMCs, by forcing the expression of reprogramming factors, Sox2, lin28, Oct4, Nanog, and Klf4, and then differentiating these cells back into VSMCs using the EB method. The resulting cell population expressed several VSMC genes and demonstrated contractile function typical of human aortic smooth muscle cells. 59 However, residual expression of 2 pluripotency-associated lentiviral transgenes in the iPSC-VSMCs suggested incomplete commitment to VSMC phenotype, casting doubt on the efficacy of this approach.
Several studies have attempted the use both the EB method and the monolayer method to assess their efficacy at generating VSMCs from hiPSCs. One study compared the 2 main methods of mesodermal VSMC generation using both human ESCs and murine iPSCs and found them both to be equally efficient at generating a KDR (kinase insert domain receptor; Flk-1 for mouse) positive, mesodermal progenitor population that could then be further differentiated toward a VSMC population using magnetic cell sorting and PDGF-BB treatment. 60 Another study demonstrated successful generation of VSMCs from hPSC-derived cardiovascular progenitor cells followed by fluorescence-activated cell sorter for VSMC enrichment using both the EB method and the monolayer method.
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Neural Crest-Derived Models
VSMCs have also been generated from iPSCs by preliminary differentiation into the neural crest developmental precursor cell. 62, 63 This can be achieved using pharmacological inhibition of BMP and TGF-β1 pathways 52 or by using small molecules to induce Wnt signaling, by GSK3 inhibition, as well as early inhibition of the SMAD (SMA/MAD homology) pathway during neuroectodermal differentiation of hESCs 64, 65 and hiPSCs. 66 These singlestep protocols can generate a higher proportion of neural crest cells by forcing hPSCs away from a neural progenitor cell fate, without the use of feeder cells or serum containing medium.
PiSPC for VSMC Derivation
Alternative methods have been performed to find a safer and more effective ways of generating VSMCs, without incurring the tumorigenic risks associated with using a pluripotent stem cell line. 67 By inducing direct differentiation of somatic cells toward a VSMC fate before complete pluripotency has been reached, resulting in a partially induced pluripotent stem cell (PiPSC) population, researchers can eliminate the tumorigenesis risk. 15, 68 Karamariti et al 68 generated PiPSCs using human embryonic lung fibroblasts nucleofected with polycistronic plasmids containing all 4 Yamanaka factors. Injection of PiPSCs into SCID (severe combined immunodeficiency) mice did not result in teratoma formation consisting of all 3 germ layers, as expected with iPSC injection. After a 4-day period of differentiation using the collagen IV monolayer method, PiPSCs expressed a full panel of VSMC markers including calponin, SMA-α and SM22α as well as elastin and collagen, characteristically seen in VSMCs of large arteries. Moreover, the authors of this study uncovered key intracellular signaling processes involved in VSMC differentiation of PiPSCs. Autosecreted glycoprotein, dickkopf WNT signaling pathway inhibitor 3 was found to be upregulated during differentiation and lentiviral-mediated knockdown prevented VSMC-specific gene expression but not overall commitment to the cardiovascular lineage, identifying it as a unique signaling molecule in the process of VSMC differentiation. Moreover, luciferase assays revealed that dickkopf WNT signaling pathway inhibitor 3 operates via the Wnt signaling pathway by promoting nuclear translocation of β-catenin to trigger SM22α transcription. Few studies using iPSC-derived VSMCs have defined VSMC differentiation pathways, and this study highlights the potential for using reprogrammed PiPSCs to elucidate key regulatory networks required for VSMC differentiation instead of iPSCs.
Application of iPSC-Derived VSMCs
One of the major advantages of iPSCs reprogramming is the opportunity that offers both clinicians and scientists to study human diseases at a cellular level while negating the need to obtain large amounts of human tissue for research. 69 Because only a small population of VSMCs can be obtained from any given tissue sample, and usually only from patients undergoing prearranged surgical treatment or in patients postmortem, deriving a large number of VSMCs from patient skin fibroblasts and other similarly abundant somatic cell types is a welcome prospect. In the case of autopsy samples, scientists only see a snapshot of end-stage disease, making it impossible to study the early stages. iPSCs provide a potential source of vascular cells useful for vascular tissue engineering. 70 Moreover, iPSCs retain the patients' genetic background, a vital component for studying genetic diseases. 71 Thus, the risk of missing important signaling processes or cellular responses to drug therapy is reduced by using patient-derived iPSCs. 72 This has potential in specialized medicine for clinicians to carry out preliminary tests on patient-derived cells to determine the efficacy of a treatment before administering it to a patient. Moreover, hiPSCs also offer an alternative approach to using animal models, thereby complying with the scientific community's overall commitment to the 3Rs (Replacement, Reduction and Refinement). The use of iPSC-derived VSMCs provides an opportunity to reduce homogeneity of sample data, which may in turn offer new molecular insights into VSMC behavior subject to embryological origin and phenotype. Finally, iPSC-derived VSMCs have the potential to improve current tissue engineering techniques, particularly in the field of vascular grafting.
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Tissue-Engineered Blood Vessels
Vascular grafts are essential for several cardiovascular diseases, including congenital heart disease, coronary bypass grafts, and vessel replacement. 75 In some cases where autologous vessels are not always a viable therapeutic option, alternative treatments involving the use of iPSC-derived vessels are a promising alternative. 13 iPSC technology provides an opportunity to construct blood vessel-like structures containing patient-derived cells such as endothelial cells and VSMCs. 68 However, in order for iPSC-derived vessels to be considered over prevailing methods, they would need to overcome a series of challenges currently faced using autologous and synthetic vessels. First, iPSC-derived VSMCs would be expected to maintain their phenotypic and functional properties within the vessel wall. Second, these iPSC-derived vessels would be expected to show much lower thrombogenic and immunogenic risk compared with current standard therapies. 69 Finally, adequate host integration of the vessel would be necessary in order for the vessel to fulfill its role as a conduit for blood flow and a regulator of vascular tone. 70 A recent study showing allogenic cells producing a matrix protein scaffold for the purpose of cell seeding, highlights just one of many functions iPSCderived VSMCs would be expected to carry out as key contributors to matrix protein architecture in blood vessels. 13, 76, 77 Researchers have already begun to explore the potential for using iPSC-derived VSMCs in tissue engineering (Figure 4) . Xie et al 77 treated iPSCs in vitro with retinoic acid (10 −5 M) forperiods and generate a lower SMC yield from both iPSCs and embryonic stem cells. 78, 79 On successful differentiation, SMA-α-positive cells were seeded onto a 3-dimensional (3D) nanofibrous poly l-lactide scaffold for subcutaneous implantation into nude mice. Gene expression analysis revealed higher expression of some (myocardin and SM22α) but not all (smoothelin and smooth muscle myosin heavy chain) VSMC markers in the iPSC-VSMC-seeded scaffolds compared with controls after 2 weeks, showing incomplete iPSC differentiation. Similarly, a different group used iPSC-derived VSMCs seeded onto nanofibrous scaffolds to test whether they could survive introduction into a living organism. iPSCs, generated from human aortic fibroblasts, were differentiated into VSMCs via the EB method and then seeded on 3D nanofibrous poly l-lactide scaffolds for 24 hours, followed by subcutaneous implantation into nude mice for 2 weeks. 69 Positive staining for SMA-α, calponin, and SM22α as well as the presence of collagen deposition in the scaffold after 2 weeks provided evidence of successful maintenance of VSMC phenotype.
Equally, some studies have used seeded iPSC-derived progenitor cells onto scaffolds to access their ability to undergo further VSMC differentiation. 80 One group used patient peripheral blood mononuclear cell-derived hiPSCs, for differentiation into cardiovascular progenitors via a mesodermal intermediate that were the seeded onto a porous nanofibrous scaffold for subcutaneous implantation into nude mice. 81 After 2 weeks, histological analysis revealed that >80% of fluorescence-labeled progenitor cells were positive for SM22α. In vitro studies showed that differentiation of these patient-specific, integration-free iPSCs with PDGF-BB and TGF-β supplementation resulted in a cell population capable of contracting in response to the muscarinic receptor agonist, carbachol, as seen with primary human aortic smooth muscle cells. The authors of this study deliberately avoided using EB formation to derive VSMCs, to reduce the likelihood of generating a heterogeneous population of VSMCs from multiple germ layers, which would result in a VSMC population lacking the distinctive physiological properties of lineage-specific VSMCs. 50, 81 Moreover, a nonviral method of reprogramming peripheral blood mononuclear cells for iPSC generation reduces the tumorigenesis risk associated with using lentivirus-based iPSCs for in vivo studies. 82, 83 Alternative tissue-engineered vessel studies have included the use of bilayered collagen scaffolds for iPSC-VSMC seeding. 84 Nakayama et al 84 showed that iPSC-derived VSMCs orientate themselves circumferentially along collagen nanofibrils when they are aligned, mimicking the behavior of primary VSMCs. These iPSC-derived VSMCs maintained positive SMA-α expression throughout the study, providing evidence of undeterred VSMC specification. Of note, the authors of this study also performed similar tests on primary endothelial cells and iPSC-derived endothelial cells. They found that monocyte adhesion was reduced for both cell types when cells were seeded onto aligned nanofibrillar scaffolds as opposed to randomly aligned nanofibrillar scaffolds. Evidence for reduced inflammatory activity offers researchers an incentive to consider seeding multiple cell types for blood vessel tissue engineering, as seen with Karamariti et al 68 who generated a vessel structure composed of VSMCs and endothelial layers. Endothelial cells and VSMCs derived from PiPSCs were seeded on top of each other to create a blood vessel structure closely resembling a mouse artery. The double-seeded vessels were transplanted into SCID mice and showed effective grafting after 3 weeks with successful incorporation into the host organism. Unlike decellularized vessels, these did not experience rupture or occlusion.
Finally, iPSC-derived vascular cells have also been considered for their use in tissue-engineered vascular grafts. 85 The iPS cell sheets containing both endothelial cells and VSMCs were seeded onto a biodegradable scaffold and implanted onto the infrarenal inferior vena cava of immunodeficient mice. Ultrasonography analysis revealed that grafts persisted after by guest on December 14, 2017 http://atvb.ahajournals.org/ Downloaded from 10 weeks; however, a significant drop in iPSC number was observed on histological examination, suggesting a decline in cell survival over time. Although the high rates of iPSC apoptosis are a painful reminder of the fundamental challenges associated with cellular engraftment techniques, the paracrine effect of iPSCs should not go unexamined. 86 Indeed the authors of this study provided evidence of neotissue formation brought about by the presence of iPSCs.
VSMC Disease Modeling
iPSC-derived VSMCs also offer the research community a unique opportunity to study vascular diseases with limited impact on patients 70 (Table) . One study generated iPSCs from VSMCs of a patient with supravalvular aortic stenosis (SVAS), to generate VSMCs (SVAS-iPSCs-VSMCs) via the EB method and study disease physiology at the cellular level. 87 SVAS is a genetic condition characterized by narrowing or complete blockage of the ascending aorta because of extensive VSMC proliferation. 94 Accordingly, SVAS-iPSCs-VSMCs demonstrated higher rates of proliferation and migration in vitro compared with iPSCs-VSMCs generated from a healthy donor. Compared with healthy iPSC-VSMCs, SVAS-iPSCs-VSMCs exhibited a 70% decrease in actin filament bundle formation despite no significant change in overall protein expression. This is known to occur because of a defect in elastin expression required for efficient contractile apparatus formation in SVASVSMCs. 87 As predicted, a significant drop in elastin expression was noted in SVAS iPSCs-VSMCs patient, establishing this as a good model for the disease in vitro. 87 Similarly, when hiPSCderived VSMCs were seeded onto ring-shaped agarose gels to form 3D tissue rings, the SVAS patient-derived rings exhibited higher cellular proliferation, decreased actin bundle filament formation, and an overall drop in contractile force. 88 Fibroblastderived iPSCs, taken from patients with Williams-Beuren syndrome, a disease characterized by SVAS, were also induced toward a VSMC phenotype. These showed similar behavioral properties to the SVAS-iPSC-VSMCs patients compared with healthy controls, providing clear evidence that alternative somatic cell sources can be used to generate iPSCs-VSMCs for modeling vascular diseases caused by genetic defects. 87 Kinnear et al 89 revealed that treatment with the mTOR (mechanistic target of rapamycin) inhibitor, rapamycin, could restore the contractile response and tubular formation of hiPSC-derived VSMCs from patients with Williams-Beuren syndrome, providing a possible therapeutic candidate in patients with SVAS.
Similarly, mTOR inhibition was found to rescue defective differentiation of neural crest cell-derived VSMCs, generated using iPSCs from peripheral blood mononuclear cells of patients with biscupid aortic valves, a congenital cardiovascular malformation resulting in thoracic aortic aneurysms and aortic dissection. 90 The authors of this study found that only immature VSMCs with impaired contractile ability could be generated from neural crest cell precursors, responsible for populating VSMCs in the ascending aorta, where biscupid aortic valve aneurysms commonly arise. In contrast, paraxial mesoderm-derived VSMCs, which populate the descending aorta, 95 generated from the same patients did not display altered phenotype or behavior. 90 The authors concluded that the use of patient-derived iPSCs offers a unique approach to understanding disease pathology and provided them with conclusive evidence that a combination of altered hemodynamics because of biscupid aortic valves as well as the immature neural crest-derived VSMCs predisposes biscupid aortic valves patients to aneurysm formation in the ascending aorta.
iPSC-VSMCs have also helped scientists to understand the underlying signaling defects in conditions such as Hutchinson Gilford Progeria syndrome, a disease associated with premature ageing in children. 91 Increased accumulation of progerin in the nucleus of iPSC-derived VSMCs results in decreased proliferation of VSMCs, hindering their ability to respond to stress and hypoxic conditions, a pertinent finding as premature atherosclerosis in patients with Hutchinson Gilford Progeria syndrome has been shown to be in part due to aberrant VSMC loss. 96 One particular study draws attention to the relative absence of nuclear defects in undifferentiated iPSCs derived from patients with Hutchinson Gilford Progeria syndrome, revealing a potential to reset nuclear function through cellular reprogramming. 92 Furthermore, these studies highlight the possibility of studying both physiological and premature aging in VSMCs in vitro.
Finally, a connective tissue disorder, known as Marfan syndrome has also been modeled using iPSC-derived VSMCs from patients. 93 The authors of this study recapitulated various aspects of the disease, including irregular fibrillin-1 deposition, and in doing so, identified several important downstream targets, including KLF4 and p38. Moreover, they restored fibrillin-1, TGF-β, and abnormal matrix metalloproteinase levels by correcting for the missense mutation in the fibrillin-1 gene using CRISPR-Cas9 system, providing strong evidence for the use of gene editing as a therapeutic tool. Therefore, iPSC technology provides a powerful tool for studying VSMC differentiation related to genetic mutations in patients by using CRISPR-Cas9 and drug screening methods.
Challenges in iPSC-Derived VSMCs
Great strides have been made in deriving VSMCs of varied lineages and phenotypes from iPSCs, and ongoing investigations into their therapeutic potential show promising results. However, several challenges exist which require close consideration, should both clinicians and scientists wish to continue to broaden their understanding of vascular diseases and their treatment using iPSCs. As we have seen, there is no single best fit protocol for generating VSMCs from iPSCs, themselves derived from several somatic cell sources via different reprogramming methods. As such, a large degree of heterogeneity can be observed among VSMCs derived from similar differentiation protocols. 74 Moreover, the existence of different VSMCs lineages, occurring as a result of germ layer formation during embryological development, further adds to the complexity of iPSC differentiation techniques. 16 Besides, groups such as Kim et al 97 have argued for a closer examination of whether reprogrammed cells retain epigenetic memory despite being fully differentiated into a different somatic cell. Although arguably, these findings would offer us a unique insight into epigenetic regulation occurring during vascular disease. Despite this, the use of iPSCs for disease modeling in general poses several problems. For instance, the embryoniclike nature of iPSCs makes modeling diseases usually seen in the elderly or in patients in the later stages of disease more difficult. 98 Thus, alternative cell types, such as skin-derived precursors, ought to be recognized for their potential as VSMC sources as they readily differentiate into VSMCs using the same growth factors required to generate VSMCs from neural crest precursors. 99 Moreover, they have been used to model type II diabetes mellitus in elderly patients, without the need for reprogramming required in iPSC generation, often resulting in erasure of disease-relevant epigenetic modifications. 100 Drug screening may also prove difficult using newly differentiated cells if pharmacotherapy is only required in the later stages of disease because newly differentiated cells will not have been exposed to environmental factors responsible for advancing pathological processes. As such, studies that incorporate environmental triggers usually seen in disease such as high sheer stress, reactive oxygen species, and 3D culture and coculture systems would help to provide a more realistic understanding of cell behavior. 74 For tissue engineering approaches, poor cellular engraftment remains an issue in stem cell-based therapies. 73 Techniques seeking to improve their adhesion and integration into host tissue are vital if iPSC-derived tissue engineering is to be pursued. Reports of transplanted stem cells releasing soluble factors, resulting in a paracrine effect on neighboring cells, 85, 86, 101 would suggest that iPSC-derived VSMCs contribute to cardiovascular repair and regeneration may occur through a similar manner as seen with the study by Hibino et al 102 using iPSC sheets.
As of yet, most cardiovascular iPSC studies have investigated iPSC-derived cardiomyocytes to determine their therapeutic benefit in regenerative medicine. [103] [104] [105] Interestingly, these studies point to the highly proinflammatory and hypoxic environment of infarcted myocardium as one of the major reasons for low cellular engraftment. To date, most studies involving vessels composed of iPSC-derived VSMCs have been conducted in uninjured models, 68, 69, 77, 78, 84, 85 and no study has investigated the use of iPSC-derived vessels in a model of vascular injury. As such, the benefit of using iPSC-derived VSMCs vessels over autologous vessels for grafting has yet to be revealed. Moreover, another issue arising from iPSC-derived VSMCs for surgical treatment is the time-consuming nature of generating patient-specific VSMCs followed by seeding onto a scaffold for 3D tissue engineering, especially in an acute setting such as a myocardial infarct where patients require immediate surgical intervention. 73 Finally, but most importantly, the risks of tumorigenesis and teratoma formation for transplanted iPS cell-derived VSMCs must be carefully considered before clinical application. Thus, as of yet the clinical benefit of iPSC technology has not reached its full potential.
Future Perspectives
The field of iPSC technology has advanced considerably over the past decade due to the advent of somatic cell-derived PSCs. 106 The technology has offered hope to clinicians and scientists wishing to study the behavior, genetics, and intracellular signaling pathways present in specialized cells such as the VSMC. As of yet, the most recent studies have only provided us a glimpse into VSMC molecular biology, but as iPSC differentiation protocols become more refined, there is hope that yet more signaling pathways will be uncovered and shed light onto VSMC behavior as well as highlight defects responsible for impaired VSMC function in disease. Moreover, iPSC-derived VSMCs are a promising tool for future vascular grafting therapies as they have the potential to replace current methods, which come with their own set of challenges. iPSC-derived VSMCs may even serve as an additional screening tool for drug development. Moreover, manipulation of iPSC-VSMC's DNA using CRISPR-Cas9 system may further advance the field of gene therapy. As evidenced above, there are a wide range of issues that must first be addressed before iPSC-derived VSMCs become introduced into the mainstream as both a therapeutic option and a research tool. As such, iPSC-derived VSMCs are a promising entity worthy of further investigation.
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